Their findings suggest that SII is notably related to prognosis in EGFR-mutant lung ADC patients receiving first-line EGFR-TKIs, with higher SII indicating greater tumor burden, more profound immunosuppression, and poorer outcomes. Here, EGFR is linked to neoplasm.